about
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob miceTissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequencesNeonatal exendin-4 treatment reduces oxidative stress and prevents hepatic insulin resistance in intrauterine growth-retarded rats.GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review.Newer therapeutic options for children with diabetes mellitus: theoretical and practical considerations.Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes.Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intakeCNS GLP-1 regulation of peripheral glucose homeostasis.Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptidesElimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the rat heart and their role in protection against ischaemia.Inositolphosphoglycans are possible mediators of the glucagon-like peptide 1 (7-36)amide action in the liver.Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dogGlucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes.Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs.Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice.Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats.GLP-1 does not acutely affect insulin sensitivity in healthy man
P2860
Q24629441-35539658-4402-4B42-A634-12B92F570CA5Q28306665-436EBDA0-A2A7-43DB-9357-345F6CC50C93Q33579205-F10018EA-59F6-4297-850E-6A60DFF94FE7Q33734024-0EF38B79-6A50-4653-9B9B-DAFE7652810FQ34589793-D36998C0-942A-4725-B029-474E9EC56068Q35962745-7488FE20-582B-4857-93FE-D296C592CDB4Q36455865-3C88BE82-A04B-44B8-A5CF-D7DF3F448A02Q36580608-02EC1167-EBAA-4F7F-9F6D-C7FBDC1535AFQ36807579-AABDD883-7349-40AD-B751-BF12E4478185Q37174896-A5F06C45-2C17-4840-938E-5E9EB35CCCB3Q37212333-879AA5A4-02F3-4A86-BC02-5D958F364124Q37351161-A6E01D99-ADAD-4A64-9A40-48DFFD5A75F9Q38342150-4612600A-68F1-4154-8B7F-50CC352699E2Q38610870-1959F6E2-3FF3-4FD0-AE28-4030BE60A463Q41231972-CEEA95DE-31FD-483D-8240-951932DF8710Q42140416-737DD9EB-BD44-40B7-AD1C-C3A17A27E161Q43781475-F67F3526-3B37-4E8C-BF6A-FDC043F3925BQ44303787-822D6CD8-BEDE-4409-AEF9-7081B93BF002Q54068522-A92C6E26-6BED-45C5-9BAA-7B5994861FCAQ54632091-B75626A9-F242-489D-8B31-D2A9F644D5D9Q58449053-BF255E7B-951F-44C6-A94B-D4D502B82F96
P2860
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Glucagon-like peptide 1: a potent glycogenic hormone.
@en
Glucagon-like peptide 1: a potent glycogenic hormone.
@nl
type
label
Glucagon-like peptide 1: a potent glycogenic hormone.
@en
Glucagon-like peptide 1: a potent glycogenic hormone.
@nl
prefLabel
Glucagon-like peptide 1: a potent glycogenic hormone.
@en
Glucagon-like peptide 1: a potent glycogenic hormone.
@nl
P2093
P2860
P1433
P1476
Glucagon-like peptide 1: a potent glycogenic hormone.
@en
P2093
Clemente F
López-Delgado MI
Valverde I
Villanueva-Peñacarrillo ML
P2860
P304
P356
10.1016/0014-5793(94)00699-7
P407
P577
1994-08-01T00:00:00Z